Spero Therapeutics expects to report data from Phase 3 trial of SPR994 in 3Q20
Spero Therapeutics announced that it will host a key opinion leader breakfast symposium on the unmet need, treatment landscape and potential for oral SPR994 as a new therapeutic option in complicated urinary tract infections, as well as the opportunity for oral SPR720 in non-tuberculous mycobacterial infections. The event will be held on Thursday, December 5, 2019, from 8:30 a.m. - 10:30 a.m. ET in New York. As part of the event, Yoav Golan, MD, MS, FIDSA, Attending Physician and Associate Professor of Medicine at the Tufts University School of Medicine, will present an overview of the burden of disease in cUTI and the potential for oral SPR994 to change the treatment landscape. If approved, SPR994 has the potential to be the first oral carbapenem antibiotic for use in adults to treat cUTI. A pivotal Phase 3 clinical trial of SPR994 for the treatment of cUTI entitled ADAPT-PO continues to enroll patients, and Spero expects to report top-line data from the Phase 3 clinical trial in the third quarter of 2020. The Company will also present an overview of the progress in the SPR720 program. SPR720 is an orally administered antimicrobial agent being developed for the treatment of a rare, orphan disease, non-tuberculous mycobacterial infections and other infections, including Mycobacterium tuberculosis. SPR720 is currently being evaluated in a double-blind, placebo-controlled Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of SPR720 in healthy volunteers. Spero expects to report top-line data from the Phase 1 clinical trial by year-end 2019.